avacincaptad pegol + Sham
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stargardt's Macular Dystrophy
Conditions
Stargardt's Macular Dystrophy
Trial Timeline
Jan 12, 2018 → Mar 31, 2025
NCT ID
NCT03364153About avacincaptad pegol + Sham
avacincaptad pegol + Sham is a phase 2 stage product being developed by Astellas Pharma for Stargardt's Macular Dystrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT03364153. Target conditions include Stargardt's Macular Dystrophy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04435366 | Phase 3 | Completed |
| NCT03364153 | Phase 2 | Completed |
Competing Products
6 competing products in Stargardt's Macular Dystrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MA09-hRPE | Astellas Pharma | Pre-clinical | 23 |
| MA09-hRPE | Astellas Pharma | Phase 1/2 | 41 |
| MA09-hRPE | Astellas Pharma | Phase 1/2 | 41 |
| hESC-RPE | Astellas Pharma | Pre-clinical | 23 |
| SAR422459 | Sanofi | Phase 1/2 | 40 |
| Long term follow up in all patients who received SAR422459 in previous study TDU13583 | Sanofi | Phase 2 | 51 |